#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians in New York can now certify cannabis for anxiety despite the lack of clinical evidence supporting its efficacy, creating a potential disconnect between regulatory approval and scientific evidence that may mislead patients about treatment effectiveness. This gap highlights the need for clinicians to counsel patients on the absence of robust data for cannabis in anxiety disorders and consider evidence-based alternatives like SSRIs or psychotherapy as first-line treatments. The approval underscores broader tensions in medical cannabis policy where regulatory decisions may outpace clinical evidence, requiring clinicians to navigate patient expectations carefully while maintaining standards of informed consent.
New York’s recent approval of cannabis for anxiety represents a significant regulatory gap between policy and clinical evidence. A Lancet Psychiatry systematic review found insufficient evidence supporting cannabinoid efficacy for anxiety disorders and post-traumatic stress disorder, yet New York’s framework now permits any licensed practitioner to certify patients for medical cannabis without specialized training or evidence-based guidelines. This regulatory decision may lead clinicians to recommend cannabis for anxiety despite limited scientific support, potentially delaying patients from evidence-based treatments such as cognitive behavioral therapy or selective serotonin reuptake inhibitors. Practitioners in New York and other jurisdictions approving cannabis for anxiety should be aware that current evidence does not demonstrate clear benefit for these conditions and should counsel patients accordingly about the gap between regulatory approval and clinical evidence. Clinicians prescribing or certifying cannabis for anxiety should emphasize that this remains an off-label use with unproven efficacy and consider whether patients might benefit more from established psychiatric interventions.
“We’ve approved cannabis for anxiety in New York based on patient demand and anecdotal reports, but we’re ignoring level-one evidence showing cannabinoids don’t actually treat anxiety disorders, and that’s a clinical mistake we’ll spend years correcting in our patients.”
🧠 New York’s recent approval of cannabis for anxiety disorders creates a clinical tension between regulatory policy and current evidence: a Lancet Psychiatry systematic review found insufficient evidence that cannabinoids effectively treat anxiety or PTSD, yet practitioners can now certify patients for medical cannabis use. This gap is particularly concerning given that cannabinoids may paradoxically worsen anxiety in some patients, especially at higher doses or with THC-predominant products, and long-term safety data remain limited. Confounding factors such as placebo effects, variable product composition, concurrent treatments, and selection bias in existing studies further complicate interpretation of patient-reported benefits. Clinicians should recognize that regulatory approval does not equate to established efficacy and should counsel patients seeking cannabis for anxiety about the lack of robust evidence, discuss alternative evidence-based treatments including SSRIs and psychotherapy, and monitor closely for symptom improvement or worsening if patients choose to use cannabis
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it: